Most important in brief
- For EGFR, ALK and ROS1, tablets are on the list, including osimertinib, alectinib, brigatinib, lorlatinib and crizotinib.
- Immunotherapy is on the list, including durvalumab after chemoradiotherapy in stage III.
- No medicine for KRAS G12C, RET, MET or NTRK is on the list.
- A tumour board proposes the treatment; usually two cycles are approved first.
What applies now
Medicines list of the FZOCG health insurance fund, October 2026 · List (PDF), all versions · checked on 16 November 2026
| Test result | Medicine | What for (simplified) |
|---|---|---|
| EGFR | osimertinib | First treatment with an EGFR mutation; with T790M; after complete surgery (stage IB–IIIA), up to 36 months. |
| EGFR | gefitinib | Advanced NSCLC with an EGFR mutation. |
| ALK | alectinib, brigatinib | First treatment or after crizotinib. |
| ALK | lorlatinib | First treatment or after earlier ALK tablets. |
| ALK, ROS1 | crizotinib | For ALK (first treatment or later) and for ROS1. |
| no EGFR or ALK | pembrolizumab | First treatment: alone if PD-L1 is 50% or more, with chemotherapy if PD-L1 is lower. A few cycles first, then continued only if it works. |
| no EGFR or ALK | atezolizumab | First treatment alone if PD-L1 is high, or with chemotherapy; also after chemotherapy. |
| Stage III | durvalumab | After chemoradiotherapy for inoperable stage III, PD-L1 1% or more, up to 12 months. |
| Chemotherapy | carboplatin, cisplatin, docetaxel, paclitaxel, gemcitabine, vinorelbine, pemetrexed | On the list. |
How to get the treatment
A tumour board proposes the treatment. Usually two cycles are approved first, then the effect is checked. The list names these tumour boards:
- Klinički centar Crne Gore, Klinika za onkologiju i radioterapiju (Podgorica)
- Opšta bolnica Bijelo Polje
- Specijalna bolnica za plućne bolesti Brezovik (Nikšić)
Not on the list
Afatinib, erlotinib, amivantamab; no medicine against KRAS G12C, RET, MET or NTRK. Dabrafenib and trametinib are listed for melanoma only.
What this means for you
If you are treated in Montenegro, tablets for EGFR, ALK and ROS1 are on the list, and durvalumab after chemoradiotherapy in stage III. A tumour board proposes the treatment, usually for two cycles first.
For KRAS G12C, RET, MET and NTRK, no medicine is on the list. Ask your care team what other ways there are.